Effectiveness of omega-3 polysaturated fatty acids (fish oil) supplementation for treating hypertriglyceridemia in children and adolescents.

Limited pharmacological options are available for management pediatric hypertriglyceridemia. We examined the effectiveness of dietary fish oil supplementation as a means to reduce triglyceride levels in pediatric patients. We reviewed 111 children aged 8 to 18 years with hypertriglyceridemia (≥1.5 mmol/L) undergoing treatment in a specialized dyslipidemia clinic. At the treating cardiologist's discretion, 60 subjects received nonprescription fish oil supplementation (500-1000 mg/d), while the remaining patients did not. Initially there were no baseline differences between groups, including the use of concomitant lipid-lowering medication. Treatment with fish oil was associated with a potential clinically relevant but non-statistically significant decrease in triglycerides and triglyceride-to-high-density lipoprotein (HDL) ratio. Fish oil had no effect on HDL-cholesterol, non-HDL-cholesterol, or total cholesterol. All associations remained unchanged when adjusted for body mass index z score, nutrition, physical activity, and screen time. Fish oil supplementation was not significantly effective in treating hypertriglyceridemia in pediatric patients.